fluorouracil.... 500 mg/sqm IV days 1 and 8.
adriamycin...... 50 mg/sqm IV day 1.
cytoxan......... 500 mg/sqm IV day 1.
FREQUENCY....... Repeat cycle every 21 days.
25. Blumenschein G, et.al. FAC chemotherapy for breast cancer.
Proc Am Soc Clin Oncol 15:193, 1974.
Hortobagyi GN. Gutterman JU. Blumenschein GR. Tashima CK.
Burgess MA. Einhorn L. Buzdar AU. Richman SP. Hersh EM.
Combination chemoimmunotherapy of metastatic breast cancer
with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
Cancer. 43(4):1225-33, 1979 Apr.
One hundred and five patients with metastatic breast cancer
were treated with 5-fluorouracil, Adriamycin, cyclophosphamide
and BCG (FAC-BCG). The results were compared to those observed
in a group of 44 patients treated with FAC chemotherapy alone.
Although the overall response rates were similar (76% for
FAC-BCG and 73% for FAC), the duration of remission was of 9
months for FAC and 14 months for FAC-BCG (p = 0.04).
Similarly, survival or responding patients treated with
FAC-BCG was significantly longer (24 months) than that
observed in the chemotherapy alone treated group (15 months).
There was no difference in survival or duration on study for
non-responders. Response rates were not influenced by dominant
site of disease, menopausal status or disease-free interval.
The duration of remission and survival, however, were
significantly longer for patients with bone and soft tissue
involvement than for patients with visceral metastasis.
Similarly patients with 1 or 2 metastatic sites survived
significantly longer than those with more than 3 organ sites
involved (p = 0.02). This chemotherapeutic combination is
highly effective in inducing remissions. In addition,
nonspecific immunotherapy with BCG appears to prolong duration
of remission and survival for responding patients.